Medical/Pharmaceuticals
Minghui Pharmaceutical Inc. Announces First Patient Dosing in Phase 1 Clinical Studies of Both the Antibody-Drug Conjugate Programs Targeting TROP-2 or B7-H3 Respectively, for Treatment of Advanced or Metastatic Solid Tumors
SHANGHAI and HANGZHOU, China and WILMINGTON, Del., June 20, 2023 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a leading clinical-stage biopharmaceutical company, announced today that the first dosing has been completed in two phase 1 clinical studies evaluating MHB036C and MHB088C. The studies a...
2023-06-20 18:30
5009
Subang Jaya Medical Centre Awarded Frost & Sullivan's Company of the Year Award for the Third Consecutive Year
SJMC's long history of clinical and service excellence and expertise in certain areas, such as oncology and orthopedics, points to its robust performance. SAN ANTONIO, June 20, 2023 /PRNewswire/ -- Frost & Sullivan assessed the Malaysian healthcare industry and, based on its findings, recognizesS...
2023-06-20 09:00
1416
Curocell announced encouraging updates on the next-generation anti-CD19 CAR-T, Anbalcabtagene-autoleucel at International Conference on Malignant Lymphoma (ICML) 2023
* 84% ORR (32 of 38 patients) and 71% CR (27 of 38 patients) documented after 2 million cells/kg dose anbal-cel treatment to patients in relapsed/refractory large B-cell lymphoma * Durable complete response was measured-68% at 1 month, 61% at 3 months, and 60% at 6 months respectively. DAEJEO...
2023-06-20 08:01
1117
Suvoda Expands Board of Directors With Addition of Clinical Trial Veteran Irena Webster
PHILADELPHIA, June 20, 2023 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, has tapped Irena Lerentracht Webster to join its board of directors.Webster is...
2023-06-20 07:00
1299
AWAK Technologies and Singapore General Hospital launch pre-pivotal clinical trial of wearable peritoneal dialysis device
SINGAPORE, June 20, 2023 /PRNewswire/ -- AWAK Technologies (AWAK) and Singapore General Hospital (SGH) announce the launch of a pre-pivotal clinical trial with the enrolment of their first subject to study the safety and efficacy of an improved Automated Wearable Artificial Kidney Peritoneal Dial...
2023-06-20 06:00
2204
Sirnaomics Advances STP705 for Squamous Cell Carcinoma In Situ into Late-Stage Clinical Development
HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 19, 2023 /PRNewswire/ -- Sirnaomics Ltd.(the "Company"; stock code: 2257, together with its subsidiaries, the"Group" or "Sirnaomics"), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced the adv...
2023-06-19 21:29
4089
Bergen Prepares to Host International Conference on Hansen's Disease Marking 150 Years Since the Discovery of the Leprosy Bacillus
TOKYO, June 19, 2023 /PRNewswire/ -- The Sasakawa Leprosy (Hansen's Disease) Initiative and theUniversity of Bergen are organizing a two-day conference in Bergen, Norway, on June 21-22, 2023, to commemorate the 150th anniversary of the discovery ofM. leprae, the causative agent of leprosy, in 187...
2023-06-19 19:00
1750
The Summit Forum on the Application and Construction of AGP in China Takes Place in Shenzhen
SHENZHEN, China, June 19, 2023 /PRNewswire/ -- On June 9, the Summit Forum on the Application and Construction of AGP inChina, led by the National Innovation Center for Advanced Medical Devices, sponsored by China AGP and Digital Therapeutics R&D Center (hereafter referred to as the "R&D Center")...
2023-06-19 16:00
1845
Allgenesis Announces Encouraging Phase 1b Data Showing AG-80308 Providing Improvements in Multiple Signs and Symptoms in Dry Eye Patients
ALHAMBRA, Calif., June 19, 2023 /PRNewswire/ -- Allgenesis Biotherapeutics Inc., a clinical-stage specialty pharmaceutical company focused on developing novel ophthalmic drugs, today announced topline data from the company's Phase1b clinical trial for AG-80308, a first-in-class, formyl peptide re...
2023-06-19 16:00
1679
Novel Transcatheter Valve Repair Device: DRAGONFLY-DMR 12-Month Trial Results Revealed at EuroPCR 2023
First-Time Clinical Trial Outcomes Show Promising Follow-Up Results HANGZHOU, China, June 19, 2023 /PRNewswire/ -- On May 17th, the 12-month results of the DRAGONFLY-DMR pivotal trial were presented at EuroPCR 2023. This trial was led by Professor Jian'an Wang from Zhe'er Hospital,Hangzhou, China...
2023-06-19 14:35
1735
TCM contributes "Chinese scripts" to Cambodia's epidemic prevention, global health governance
BEIJING, June 19, 2023 /PRNewswire/ -- A news report by haiwainet.cn: In recent years, Chinese hospitals, represented by Xiyuan Hospital under the China Academy of Chinese Medical Sciences, have made remarkable progress in overseas traditional Chinese medicine(TCM) clinics, training and exchange...
2023-06-19 13:51
1634
First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring Indication Expansion
MELBOURNE, Australia, June 19, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase II study of the Company's carbonic anhydrase- (CAIX)-targeting PET/CT[1] imaging agent TLX250-CDx (89Zr-DFO-girentuxima...
2023-06-19 08:16
2009
Mallinckrodt Announces Publication of Real-World Data on the Use of Extracorporeal Photopheresis (ECP) in Heart Transplant Patients
- Results from the largest European and first multicenter, retrospective, observational chart review study investigating the real-world use of ECP in heart transplant patients reinforce its use as a treatment for heart transplant rejection and prevention of rejection1 - DUBLIN, June 19, 2023 /PR...
2023-06-19 06:30
2704
The 'Penicillin' of Antivirals, Xafty by Hyundai Bioscience, Opened a New Era of Treating Respiratory Viral Infections with Single Drug
- Professor Heungjeong Woo of Hallym University College of Medicine, announced the result of Xafty's clinical study at Emerging Science Session of the American Society for Microbiology (ASM) Microbe 2023 - Dr. Jo White evaluated Xafty's clinical results as "The birth of Penicillin of Antivirals"...
2023-06-18 03:30
4132
Molfix Bond with Love Secure Attachment Bond Program was Honored with The International CSR Excellence Awards in its 5th Year
Bond with Love Secure Attachment Bond Program of Molfix, which supports the happy and healthy development of babies and is a reliable companion of mothers with its innovative approach, was honored with "The International CSR Excellence Awards" LONDON, June 17, 2023 /PRNewswire/ -- Molfix Bond wi...
2023-06-17 13:00
3250
MoyoAssist® Extra-VAD, a Promising Solution for Short-to-Medium-Term Ventricular Assist for China NMPA trial, Showcased at 4th Academic Annual Conference of CSBE
SUZHOU, China, June. 17, 2023 /PRNewswire/ -- The 4th Academic Annual Conference held by the Mechanical Circulatory Support (MCS) Branch of the Chinese Society of Biomedical Engineering (CSBE), one of the biggest academic gatherings that celebrate the latest accomplishments in technological inn...
2023-06-17 07:08
4027
MoyoAssist® Extra-VAD, a Promising Solution for Short-to-Medium-Term Ventricular Assist for China NMPA trial, Showcased at 4th Academic Annual Conference of CSBE
SUZHOU, China, June. 16, 2023 /PRNewswire/ -- The 4th Academic Annual Conference held by the Mechanical Circulatory Support (MCS) Branch of the Chinese Society of Biomedical Engineering (CSBE), one of the biggest academic gatherings that celebrate the latest accomplishments in technological inn...
2023-06-17 07:04
3965
The U.S. FDA Approved the Phase I/II Clinical Trial Application to Evaluate LBL-033, An Anti-MUC16/CD3 Bispecific Antibody Developed by Leads Biolabs, in Advanced Solid Tumors Including Ovarian Cancer
NANJING, China, June 16, 2023 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs" or "Company") today announces that the phase I/II clinical trial application for LBL-033, an anti-MUC16/CD3 bispecific antibody, for the treatment of ovarian cancer and other m...
2023-06-16 22:01
2364
SeekIn paves the way for cancer early detection in low- and middle-income countries
OncoSeek® is a revolutionary multi-cancer early detection (MCED) test developed by SeekIn and empowered by AI technology to significantly reduce the false positive rate compared to the conventional clinical method thus increasing the specificity from 56.9% to 92.9%. In all cancer types, the overa...
2023-06-16 21:00
2289
Cholesgen to enter into a drug discovery collaboration and licensing option agreement in hypercholesterolemia with AstraZeneca
SHANGHAI, June 16, 2023 /PRNewswire/ -- Cholesgen (Shanghai) Co.Ltd. ('Cholesgen') today announced an exciting new collaboration to advance research and development in hypercholesterolemia and related metabolic diseases with AstraZeneca. This three-year collaboration aims to validate genetic drug...
2023-06-16 18:00
2404
Week's Top Stories
Most Reposted
Agoda releases generative AI film to capture the joy of travel
[Picked up by 349 media titles]
2024-12-10 10:00
Mastercard Economics Institute: APAC growth expected to hold steady in 2025; global policy resets may see shift in gears
[Picked up by 313 media titles]
2024-12-10 09:00Building Asia's Future: Omni HR Secures $7.4mn for HR Tech Expansion
[Picked up by 306 media titles]
2024-12-09 10:00
CCTV+: Yuhang Journey ǀ Follow Olivier to Explore Ancient Liangzhu and Savor Jingshan Tea
[Picked up by 283 media titles]
2024-12-08 20:076th HIIFF Closes with Golden Coconut Award Ceremony
[Picked up by 282 media titles]
2024-12-11 22:19
Most Read
Agoda releases generative AI film to capture the joy of travel
2024-12-10 10:00
3697
Blokees' Figures from Multiple IPs Amaze Fans at 2024 Singapore Comic Con
2024-12-08 00:23
3553
Building Asia's Future: Omni HR Secures $7.4mn for HR Tech Expansion
2024-12-09 10:00
3473